ArticleBMC pulmonary medicine2026
Hemodynamic improvement but worsening hypoxemia after balloon pulmonary angioplasty: severe eosinophilic asthma unmasked in CTEPH.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a patient with peripheral-type chronic thromboembolic pulmonary hypertension (CTEPH) in whom exertional hypoxemia and dyspnea worsened despite substantial hemodynamic improvement after repeated balloon pulmonary angioplasty (BPA), prompting reassessment for a competing ventilatory limitation. Optimization of concomitant severe eosinophilic asthma with benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, and sinus surgery improved airflow obstruction and oxygenation and was accompanied over time by a further reduction in pulmonary arterial pressure. These changes suggest that a superimposed hypoxia-related pulmonary vascular component, compatible with group 3 physiology, may have been attenuated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.